An increased risk of both invasive and superficial fungal infections was observed among patients who received TNF-α inhibitors for various conditions.

Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a Phase II trial. Preliminary ...

Led by AbbVie’s Humira, biologic TNF inhibitors transformed the treatment of autoimmune diseases over the past 20 years. However, the biologic modality can cause adverse effects and loss of ...

Tocilizumab is effective and safe for rheumatoid arthritis, with long-term studies supporting its use and comparable cardiovascular risk to tumor necrosis factor inhibitors. Real-world data ...

BRD4, a member of the BET protein family, plays a critical role in cancer progression by regulating oncogenes, particularly MYC, which drives tumor growth but is difficult to target directly.

Image credit: Shutterstock / LCV Sanofi will halt the development of its oral tumour necrosis factor (TNF) inhibitor balinatunfib as a monotherapy after it failed to reach the primary endpoint in a ...

The drug performed better than placebo on clinical, symptomatic, endoscopic and histologic endpoints regardless of previous failure to TNF inhibitors, other biologic therapies or Pfizer's JAK ...

Axial spondyloarthritis (axSpA) clinical trials showed improved diversity, with increased representation of Asian and Hispanic/Latino participants. However, Black and Native Hawaiian/Pacific ...

Patrick Aiyes, senior immunology analyst at GlobalData, notes that the immunology market has seen a continuous increase in the sales of interleukin inhibitors and a decrease in the sales of TNF ...

TNF-inhibitors have several different safety issues than rituximab, tocilizumab and anakinra, and these distinctions may be important for certain RA patients. The risk/benefit ratio for the ...